Category Archives: Seeking Alpha article

What Should Celgene Shareholders Do In Light Of The Bristol-Myers Squibb Deal?

Celgene (NASDAQ:CELG) stock appreciated about 21% as of writing, as there was news that Bristol-Myers Squibb (NYSE:BMY) was acquiring Celgene for about $74 billion.

What Should Celgene Shareholders Do?

The news actually pushed Celgene stock meaningfully closer to its fair value, according to Thomson Reuters‘ mean 12-month target of $105. As of writing, Celgene is trading at $80.84. So, it doesn’t make sense to sell at the current levels, as there’s still about $14 (nearly 17%) of upside according to BMY’s current stock price.

At the same time, there’s a risk that if the deal breaks down, Celgene stock could come tumbling down.

If you bought Celgene in the $60s in December, you’re now sitting on some nice gains, and no one will blame you for securing and booking the profit.

For those who have a longer-term investment horizon, it may be worthwhile to wait it out. If BMY combines with Celgene, it could be a good thing, as it merges the quality biotech and pharma companies to make a more diversified firm. Moreover, BMY also offers a stable dividend to give immediate returns.

Investor Takeaway

BMY is getting a good deal here. It’s paying a low multiple for Celgene, which has a higher margin and higher growth rate – BMY’s recent net margin and consensus estimated growth rate are 6.5% and 11-12.8%, respectively, while Celgene’s are 19.6% and 19.5-19.8%. BMY also has a stronger balance sheet than Celgene. Assuming the deal goes through, I think BMY is a better buy here.

The above is an excerpt. Read the full article here: What Should Celgene Shareholders Do In Light Of The Bristol-Myers Squibb Deal?

If you like what you've just read, consider subscribing via the "Subscribe Here" form at the top right so that you will receive an email notification when I publish a new article.

Disclosure: At the time of writing, the author owns CELG.

Disclaimer: I am not a certified financial advisor. This article is for educational purposes, so consult a financial advisor and or tax professional if necessary before making any investment decisions.

Get Exclusive Articles from me on Seeking Alpha

  • Access my portfolio of high-quality U.S. and Canadian dividend stocks.
  • Real-time updates of when I buy or sell from this portfolio.
  • Get best ideas of the top 3 dividend stocks from my watchlist. Updated each month.
Learn More

Why Scotiabank May Not Be As Great As You Think

Summary
  • Bank of Nova Scotia is Canada’s most international bank with a focus on the Pacific Alliance countries.
  • In the past 10 years, the bank’s earnings-per-share growth versus its share count growth was pretty poor compared to its peers.
  • The stock has underperformed its peers but has outperformed the market.
  • Scotiabank’s dividend yield of 4.7% is safe, and you can expect stable dividend growth from the bank.

As the third-largest Canadian bank by market cap, Bank of Nova Scotia (TSX:BNS)(NYSE:BNS) or Scotiabank is often viewed as a blue-chip dividend growth stock. However, it may not be as great an investment as you think.

First, here’s an overview of the bank.

Business Overview of Bank of Nova Scotia

Scotiabank is Canada’s most international bank, but it still generates about half of its earnings from Canada. Its Canadian Banking segment is secure and generated the highest return on equity (“ROE”) of 22.7% in fiscal 2018 compared to the ROE of 14.4% and 16%, respectively, for its International Banking segment and its Global Banking and Markets segment. The overall ROE was decent at 14.9%.

Read More

Boeing: Should You Buy The Best-Performing Defense Stock Now?

Summary

  • Boeing outperforms its peers and the market in multiple periods.
  • Boeing has a strong backlog of seven years-plus based on current production capacity.
  • Applications of new technologies throughout Boeing’s business will allow for margin expansion to the mid-teens by 2020 and further expansion beyond that.
  • The stock has been in consolidation mode year to date. So, it’s a good time to dig further into the company to see if it fits your portfolio.

Aerospace and defense stocks have finally taken a breather and are in consolidation. As I was reviewing a potential dividend-growth stock to buy from the group, I noticed that Boeing (NYSE:BA) has outperformed its peers, including Lockheed Martin (NYSE:LMT), General Dynamics (NYSE:GD), and Raytheon (NYSE:RTN) and the market in different periods, including the year-to-date, one-year, three-year, five-year, and 10-year periods.

A Business Overview

Boeing is the world’s biggest aerospace company. It’s also the leading manufacturer of commercial airplanes and defense, space and security systems and a key provider of government and commercial aerospace services.

Boeing supports airlines and the U.S. and allied government customers in 150-plus countries. Last year, its global services segment made up about 15.6% of revenue. Year to date, this segment grew 11%, which will help stabilize its overall business performance as this business is non cyclical, unlike the commercial aerospace industry.

Read More